In ITP, thrombopoietin receptor agonists (TPO-RAs) such as romiplostim and eltrombopag exhibit substantial enhancements in platelet response rates and durable responses compared to placebo [46-48]. Here, MPL is linked to autoimmune thrombocytopenic purpura.